Besser, Martin
O’Sullivan, Sian Bissell
Bourke, Siobhan
Longworth, Louise
Barcelos, Giovanna Tedesco http://orcid.org/0009-0009-1756-1190
Oluboyede, Yemi
Funding for this research was provided by:
Pfizer (Pfizer)
Article History
Received: 2 May 2024
Accepted: 30 August 2024
First Online: 26 September 2024
Declarations
:
: The study was approved on March 17, 2022, by an independent ethics reviewer working under the auspices of the Association of Research Managers and Administrators.
: All individual participants included in the study were voluntary and provided electronic informed consent for their anonymous responses to be used as part of the online survey. A general consent form was completed at the beginning of the survey asking participants if they agreed to be part of the research described to them. A second question confirmed that participants had received verbal consent from the person or people they care for and that they were content for the participant to share anonymous information about their diagnosis, treatment, and symptoms. Invited participants who did not provide consent could not complete any further questions in the survey.
: Not applicable.
: Financial interests: MB received support from Novartis in the form of travel grants and support for a clinical service as well as advisory boards. Octapharma advisory board, Terumo honorarium and support for a patient event, Global Blood Therapeutics advisory board, Hemeo advisory board, Pfizer honorarium and educational support, Forte advisory board, Primeglobal honorarium, Agios advisory board and support for a patient event. SB, YO, and LL are full-time employees of Putnam PHMR. GTB is a full-time employee and equity ownership of Pfizer.